903886-71-5

Basic information

• Product Name: 6-isopropoxypyridin-3-ol
• Synonyms: 6-isopropoxypyridin-3-ol
• CAS NO: 903886-71-5
• Molecular Formula: C8H11NO2
• Molecular Weight: 153.17844
• Mol File: 903886-71-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-isopropoxypyridin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-isopropoxypyridin-3-ol(903886-71-5)
• EPA Substance Registry System: 6-isopropoxypyridin-3-ol(903886-71-5)

Safety Data

• Hazardous Substances Data: 903886-71-5(Hazardous Substances Data)

Upstream product

• 870521-31-6 5-bromo-2-isopropoxy-pyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 2402-77-9 2,3-dichloro-pyridine 
• 1344997-94-9 3-chloro-2-isopropoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1355066-41-9 5-chloro-6-(1-propan-2-yloxy)-3-pyridinol 
• 282723-22-2 2-Isopropoxy-3-chloropyridine 

Relevant articles and documents

3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel

Bedaquiline is a new drug of the diarylquinoline class that has proven to be clinically effective against drug-resistant tuberculosis, but has a cardiac liability (prolongation of the QT interval) due to its potent inhibition of the cardiac potassium channel protein hERG. Bedaquiline is highly lipophilic and has an extremely long terminal half-life, so has the potential for more-than-desired accumulation in tissues during the relatively long treatment durations required to cure TB. The present work is part of a program that seeks to identify a diarylquinoline that is as potent as bedaquiline against Mycobacterium tuberculosis, with lower lipophilicity, higher clearance, and lower risk for QT prolongation. Previous work led to the identification of compounds with greatly-reduced lipophilicity compounds that retain good anti-tubercular activity in vitro and in mouse models of TB, but has not addressed the hERG blockade. We now present compounds where the C-unit naphthalene is replaced by a 3,5-dialkoxy-4-pyridyl, demonstrate more potent in vitro and in vivo anti-tubercular activity, with greatly attenuated hERG blockade. Two examples of this series are in preclinical development.

PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to t

CHEMICAL COMPOUNDS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Het1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain